8th May, 2024

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: USFDA inspection at Company's manufacturing facility in Kurkumbh, Maharashtra, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at manufacturing facility of the Company located in Kurkumbh, Maharashtra, India from 29th April, 2024 to 8th May, 2024.

On conclusion of the inspection, the Company has received 1 inspectional observation in Form 483. The Company will work closely with the USFDA and is committed to address this observation comprehensively within stipulated time.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2024.05.08 13:49:13 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode